Strategies to promote HDL-C: An emerging therapeutic target

European Heart Journal

Volumn 26, Issue 9, 2005, Pages 853-855

  Nicholls, Stephen J ^a   Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ACUTE HEART INFARCTION; CHOLESTEROL BLOOD LEVEL; EDITORIAL; HEART MUSCLE ISCHEMIA; HUMAN; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; TREATMENT PLANNING;

CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CORONARY DISEASE; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 18744362165     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi218     Document Type: Editorial

References (10)

1. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
2. Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
3. Olsson AG, Schwartz GG, Szarek M et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:890-896. First published on March 11, 2005, doi:10.1093/eurheartj/ ehi186.
4. Barter P, Kastelein J, Nunn A et al. High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis 2003;168:195-211.
5. Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517.
6. Brown BG, Zhao X-Q, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. Engl J Med 2001;345:1583-1592.
7. Barter PJ, Chapman MJ, Hennekens CH et al. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167.
8. Brousseau ME, Schaefer EJ, Wolfe ML et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Eng J Med 2004;350:1505-1515.
9. Nissen SE, Tsunoda T, Tuzcu EM et at. Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-2300.
10. Zheng L, Nukuna B, Brennan ML et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004;114:529-541.